Consult its monograph (www.pfizer.ca, Product Monograph PrLYRICA(R), 2020), in particular, Ophthalmological Effects (in Contraindications, p. 6) and Eye disorders (in Adverse Reactions, p. 32).
Pregabalin has been found to have a significant association with some eye-related adverse events, but, in answer to your question, as of 2020 it is not yet known whether these findings are clinically relevant.
The eye disorders principally include blurred vision (amblyopia, 6% pregabalin vs. 2% placebo) and seeing double (diplopia, 2% pregabalin
vs. 0.5% placebo). Pregabalin has also been associated with visual disturbance and vision loss. Eye disorders accounted for approximately 1% of the reasons given by pregabalin-administered subjects who chose to withdraw from treatment.
Visual acuity was found to be reduced in 7% of pregabalin-administered subjects, but 5% of placebo-administered subjects showed a reduction, so it is not so much worse than it would have been anyway.